In addition, RGCC knockdown cells or tumor cells treated with Volasertib, Dorsomorphin, or etomoxir (a fatty acid oxidation inhibitor) had a reduced NADPH/NADP + ratio (Fig. S5F) and increased ROS levels (Fig. 7F). This evidence concerns the gene RGCC and neoplasm.